Obi S
Nihon Sanka Fujinka Gakkai Zasshi. 1987 May;39(5):792-8.
HTSCA was used to study the chemotherapy sensitivity of gynecological malignant tumors. 34 specimens were obtained from 32 patients. 11 of the 34 specimens (32%) yielded a sufficient number of colonies for testing. On these, 51 separate drug assays were done, each at the 1/10 peak plasma level. 20 drugs were identified as active among 51 drugs tested. Clinical correlations of sensitivity (S) and resistance (R) were studied in 6 patients treated with combination therapies, including drugs selected on the basis of in vitro sensitivity. (formula; see text) We conclude that HTSCA can aid in identifying active drugs for use in designing treatment protocols. However, because of difficulty in preparing a single cell suspension, and the small proportion of tumors suitable for testing, HTSCA will not be used in routine drug sensitivity testing until these drawbacks are eliminated.
采用人肿瘤单细胞克隆药敏分析法（HTSCA）研究妇科恶性肿瘤的化疗敏感性。从32例患者身上获取了34个标本。34个标本中有11个（32%）产生了足够数量的集落用于检测。在这些标本上，进行了51次单独的药物检测，每次检测药物浓度均为血浆峰值水平的1/10。在所检测的51种药物中，有20种被确定为有活性。对6例接受联合治疗的患者进行了敏感性（S）和耐药性（R）的临床相关性研究，联合治疗药物是根据体外敏感性选择的。（公式；见正文）我们得出结论，HTSCA有助于识别用于设计治疗方案的活性药物。然而，由于制备单细胞悬液存在困难，且适合检测的肿瘤比例较小，在这些缺点消除之前，HTSCA不会用于常规药物敏感性检测。
